JPRN-jRCT2032200415已完成3 期
Double-blind, placebo-controlled, parallel-group study comparing the therapeutic effects of seasonal allergic rhinitis treatment sheet (HATS-03) for patients with seasonal allergic rhinitis (Verification Trial).
Okazaki Narumi0 个研究点目标入组 257 人开始时间: 2021年3月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 257
研究概览
简要总结
There is no difference in safety between test device and placebo. It was also suggested that the test device had potential possibility of usefulness for patients with seasonal allergic rhinitis though the test device could not show significant efficacy value to placebo in primary endpoints.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •(1) Seasonal allergic rhinitis (three main signs of paroxysmal recurrent sneezing, watery rhinorrhea, nasal congestion) for the past two years, and who is taking drug therapy or pollen antigen removal therapy (mask, nasal irrigation) .
- •(2) Patients with serum-specific IgE antibody (cedar score of 2 or more)
- •(3) Patients with more than 8 points in total nasal symptom score (sneezing attack score, nasal discharge
- •score, nasal congestion score, nasal pruritus score, i.e. 4TNSS) on the day of screening commencement by
- •principal- or sub- investigators.
- •(4) Patients with more than 7 points of 4 TNSS baseline scores and more than 2 points of of nasal conges-
- •tion scorerecorded in e-PROn 4TNSS.
- •(5) Patients who can stop drug therapy or pollen antigen removal therapy (mask, nasal washing) for the treatment of allergic rhinitis after obtaining consent.
- •(6) Patients who do not take drug therapy for the treatment of allergic rhinitis within the previous 7 days, including the start of the treatment period (the date of delivery of the investigational device: day 0).
- •(7) From the starting date of screening through treatment period and to the end date of the use of the trial
- •device (day 14), patients who do not have plans to go outside three prefectures (Tokyo, Kanagawa,
- •Saitama, Chiba) for more than 3 days (eg 2 day trips or 2 days and 1 night).
- •(8) Patients who can enter subjective symotoms into e-PRO by themselves
- •(9) Persons aged 20 to 65 at the time of consent acquisition.
- •(10) Participants who can receive explanations of the study in advance, understand the contents, and
- •obtain the written consent of the subject oneself.
排除标准
- •(1) Perennial allergic rhinitis patients who have nasal discharge or nasal congestion throughout the year
- •(2) Patients with bronchial asthma within 2 years before obtaining consent
- •(3) Patients who meet the following within one year before the start of the treatment period
- •1) Allergen immunotherapy (subcutaneous, sublingual) for the treatment of hay fever. Provided that ; those who used steroid collunarium during ceder pollinosis season (January to May) are excluded.
- •2) Patients who have undergone surgery (including laser treatment) on the nose
- •(4) Patients with inflammation of the upper or lower respiratory tract, nasal diseases (nasal mushrooms, nasal septum curvature, hypertrophic rhinitis) affecting the efficacy at screening and at the beginning of the treatment period (day 0) or Person who used immunological suppressor
- •(5) A person who has a skin disease or a wound on the site (nose, cheek, lips, chin) where the test device and the device holder
- •(6) Persons who have a predisposition to metal (silver, titanium) allergy
- •(7) Participants in other clinical trials within 12 weeks before obtaining consent
- •(8) Participants in other clinical trials within 12 weeks before obtaining consent
- •(9) Pregnant and possibly pregnant (pre-menopausal women confirmed by pregnancy test), patients wishing to become pregnant or nursing during the study period
- •(10) Any other person judged by the investigator or investigator to be inappropriate for this study
研究者
相似试验
已完成
3 期
Clinical study on therapeutic effects of seasonal allergic rhinitis treatment sheet (HATS-03).Seasonal allergic rhinitisJPRN-jRCT2032190215210
已完成
3 期
ME2112 Phase III (ME2112-2)SchizophreniaJPRN-jRCT2080222769Meiji Seika Pharma Co., Ltd.400
已完成
1 期
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic KeratosisActinic KeratosisNCT01742663Taro Pharmaceuticals USA435
已完成
不适用
Double-blind placebo-controlled comparative study for the efficacy of treatment on the patient with NERD between omeprasole versus omeprasole plus mosapride citrateJPRN-UMIN000000927Hyogo College of Medicine200
已完成
1 期
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.Actinic KeratosisNCT01788007Taro Pharmaceuticals USA443